9EP.F - Enanta Pharmaceuticals, Inc.

Frankfurt - Frankfurt Delayed price. Currency in EUR
49.60
-0.90 (-1.78%)
As of 7:48PM CET. Market open.
Stock chart is not supported by your current browser
Previous close50.50
Open50.50
Bid49.60 x 15600
Ask0.00 x 15300
Day's range49.60 - 50.50
52-week range49.60 - 92.75
Volume155
Avg. volume2
Market cap953.674M
Beta (5Y monthly)0.89
PE ratio (TTM)22.44
EPS (TTM)2.21
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Enanta to Host Conference Call on February 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2019, after the U.S. markets close on February 6, 2020. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

  • Business Wire

    Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update on its research and development programs in respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis (PBC), introduce its newest program in human metapneumovirus (hMPV), as well as provide an update on its business outlook for 2020, during Enanta’s presentation at the 38th Annual J.P. Morgan Healthcare Conference on January 13, 2020 at 2:30 p.m. Pacific Time.

  • Business Wire

    Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will make a formal presentation at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. Pacific Time. The presentation will contain a business overview and an update on Enanta’s research and development programs. A separate question and answer session with investors will follow the presentation and will be webcast.

  • Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript

    ENTA earnings call for the period ending June 30, 2019.

  • Associated Press

    Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Watertown, Massachusetts-based company said it had net income of 20 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...

  • Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript
    Motley Fool

    Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript

    ENTA earnings call for the period ending December 31, 2018.

  • Associated Press

    Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot

    The Watertown, Massachusetts-based company said it had net income of $1.25 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more